



## *Poly Medicure Ltd.*

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA  
Tel : +91-11-26321838, 26321881, 26321899, 26321889, 26321893, Fax : +91-11-26321894, 26321839  
E-mail : info@polymedicure.com Website : www.polymedicure.com  
CIN : L40300DL1995PLC066923

**Dated: 08<sup>th</sup> August, 2016**

**Scrip Code : 531768**

**Scrip Code : POLYMED**

**The Manager,  
Department of Corporate Services,  
Bombay Stock Exchange Limited  
Phirozee Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.**

**The Manager,  
Department of Corporate Services,  
National stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G- Block  
Bandra Kurla Complex, Bandra (E), Mumbai-400051**

**Subject: Outcome of Board Meeting of the Company**

**Ref: Compliance of Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**



Pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, We are pleased to inform the Stock Exchange that, the Board of Directors at their meeting held today i.e. 08<sup>th</sup> August, 2016 at 232-B, 3rd Floor, Okhla Industrial Estate, Phase – III, New Delhi – 110020 has approved.

- the Un-Audited Financial Results along with Limited Review Report for the First Quarter ended on 30th June, 2016.
- Other Normal Business.

Kindly acknowledge the receipt of the same.

Thanking You,

**For Poly Medicure Limited**

  
  
Avinash Chandra  
**Company Secretary**

*Encl: Unaudited Financial Results along with Limited Review Report*

(₹ In lacs)

Particulars	Standalone			Year ended
	Quarter ended			
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	(Unaudited)			(Audited)
<b>1 Income from operations</b>				
a Net sales / income from operations (net of excise duty)	10,102.67	10,512.44	9,451.12	38,972.08
b Other operating income	166.11	163.67	79.07	475.76
<b>Total income from operations (net)</b>	<b>10,268.78</b>	<b>10,676.11</b>	<b>9,530.19</b>	<b>39,447.84</b>
<b>2 Expenses</b>				
a Cost of materials consumed	3,565.05	3,210.22	3,442.24	13,177.29
b Purchases of stock-in-trade	171.90	154.23	143.77	676.13
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	(253.93)	265.72	66.14	200.25
d Employee benefits expense	1,989.14	1,853.94	1,571.06	6,899.23
e Depreciation and amortisation expense	533.09	509.11	517.69	2,018.79
f Other expenses	2,482.59	2,577.25	2,505.69	10,048.79
<b>Total expenses</b>	<b>8,487.84</b>	<b>8,570.47</b>	<b>8,246.59</b>	<b>33,020.48</b>
<b>3 Profit from operations before other income, finance costs and exceptional items (1-2)</b>	<b>1,780.94</b>	<b>2,105.64</b>	<b>1,283.60</b>	<b>6,427.36</b>
4 Other income	203.20	194.26	171.17	838.50
<b>5 Profit from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>1,984.14</b>	<b>2,299.90</b>	<b>1,454.77</b>	<b>7,265.86</b>
6 Finance costs	187.63	205.45	199.49	778.24
7 Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	<b>1,796.51</b>	<b>2,094.45</b>	<b>1,255.28</b>	<b>6,487.62</b>
8 Exceptional items	-	-	-	-
<b>9 Profit from ordinary activities before tax (7 + 8)</b>	<b>1,796.51</b>	<b>2,094.45</b>	<b>1,255.28</b>	<b>6,487.62</b>
10 Tax expense	530.13	653.89	279.90	1,756.87
<b>11 Net Profit from ordinary activities after tax (9 - 10)</b>	<b>1,266.38</b>	<b>1,440.56</b>	<b>975.38</b>	<b>4,730.75</b>
12 Extraordinary items	-	-	-	-
<b>13 Net Profit for the period (11 + 12)</b>	<b>1,266.38</b>	<b>1,440.56</b>	<b>975.38</b>	<b>4,730.75</b>
14 Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,205.67	2,205.67
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				20,177.89
16 Earnings per share (before extraordinary items) (Quarterly not annualised and yearly annualised) :				
Basic (₹)	2.87	3.27	2.21	10.72
Diluted (₹)	2.87	3.27	2.21	10.72

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 8th August, 2016 and have also been limited reviewed by Statutory Auditor of the Company.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi

Date : 08.08.2016

By order of the Board

*Himanshu Baid*

Himanshu Baid

Managing Director



# DOOGAR & ASSOCIATES

Chartered Accountants

## LIMITED REVIEW REPORT

### **The Board of Directors**

Poly Medicure Limited

232B, 3<sup>rd</sup> Floor, Okhla Industrial Estate,  
Phase III, New Delhi – 110 020.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended June 30<sup>th</sup>, 2016. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015 ( the "Listing Regulations, 2015"), which has been initiated by us for identification purposes. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the "Listing Regulations, 2015", including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Doogar & Associates**

Chartered Accountants

Reg. No. 000561N

New Delhi

  
(M. S. Agarwal)

Partner

M. No. 86580

Place of signature: New Delhi

Date of signature: 08/08/2016.